BACKGROUND: Primary central nervous system (CNS) post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication of solid organ transplantation. The objectives of this study were to define the clinical, radiologic, and pathologic features of this disease and to explore the impact of treatment on patient outcomes. METHODS: The authors reviewed the databases of participating institutions of the International Primary CNS Lymphoma Collaborative Group for cases of PCNS-PTLD. Thirty-four patients who had pathologically confirmed PCNS-PTLD without evidence of systemic PTLD were investigated retrospectively. RESULTS: The median time from transplantation to diagnosis of PCNS-PTLD was 4.4 years. Disease usually was multifocal and involved any location of the brain but was most common in the cerebral hemispheres, usually in the subcortical white matter or basal ganglia. Radiographically, all lesions enhanced either homogenously or in a ring-enhancing pattern. Cerebral biopsy was required to establish diagnosis in most patients. Most patients had monomorphic, Epstein-Barr virus (EBV)-positive disease of B-cell origin. Response rates were high regardless of treatment type, and the median survival was 47 months. Age was the only factor predictive of survival. CONCLUSIONS: The current study demonstrated that PCNS-PTLD is typically an EBV-induced B-cell lymphoma that is responsive to treatment with favorable survival in many patients. An aggressive approach to tissue confirmation of diagnosis and treatment with chemotherapy or radiotherapy should be strongly considered.
BACKGROUND:Primary central nervous system (CNS) post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication of solid organ transplantation. The objectives of this study were to define the clinical, radiologic, and pathologic features of this disease and to explore the impact of treatment on patient outcomes. METHODS: The authors reviewed the databases of participating institutions of the International Primary CNS Lymphoma Collaborative Group for cases of PCNS-PTLD. Thirty-four patients who had pathologically confirmed PCNS-PTLD without evidence of systemic PTLD were investigated retrospectively. RESULTS: The median time from transplantation to diagnosis of PCNS-PTLD was 4.4 years. Disease usually was multifocal and involved any location of the brain but was most common in the cerebral hemispheres, usually in the subcortical white matter or basal ganglia. Radiographically, all lesions enhanced either homogenously or in a ring-enhancing pattern. Cerebral biopsy was required to establish diagnosis in most patients. Most patients had monomorphic, Epstein-Barr virus (EBV)-positive disease of B-cell origin. Response rates were high regardless of treatment type, and the median survival was 47 months. Age was the only factor predictive of survival. CONCLUSIONS: The current study demonstrated that PCNS-PTLD is typically an EBV-induced B-cell lymphoma that is responsive to treatment with favorable survival in many patients. An aggressive approach to tissue confirmation of diagnosis and treatment with chemotherapy or radiotherapy should be strongly considered.
Authors: S M O'Brien; H Kantarjian; D A Thomas; F J Giles; E J Freireich; J Cortes; S Lerner; M J Keating Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Sameek Roychowdhury; Ruoqi Peng; Robert A Baiocchi; Darshna Bhatt; Srinivas Vourganti; John Grecula; Nilendu Gupta; Charles F Eisenbeis; Gerard J Nuovo; Weilian Yang; Petra Schmalbrock; Amy Ferketich; Melvin Moeschberger; Pierluigi Porcu; Rolf F Barth; Michael A Caligiuri Journal: Cancer Res Date: 2003-03-01 Impact factor: 12.701
Authors: Renaud Snanoudj; Antoine Durrbach; Véronique Leblond; Sophie Caillard; Bruno Hurault De Ligny; Christian Noel; Eric Rondeau; Bruno Moulin; Marie-France Mamzer-Bruneel; Catherine Lacroix; Bernard Charpentier Journal: Transplantation Date: 2003-09-27 Impact factor: 4.939
Authors: Amilcar A Castellano-Sanchez; Shiyong Li; Jiang Qian; Anand Lagoo; Edward Weir; Daniel J Brat Journal: Am J Clin Pathol Date: 2004-02 Impact factor: 2.493
Authors: M Wu; J Sun; Y Zhang; F Huang; H Zhou; Z Fan; L Xuan; G Yu; X Guo; M Dai; R Feng; Q Liu Journal: Bone Marrow Transplant Date: 2015-11-23 Impact factor: 5.483
Authors: Heiner Zimmermann; Mirko Nitsche; Christiane Pott; Petra Reinke; Nina Babel; Robert M Hermann; Ingeborg A Hauser; Dennis Hahn; Matthias Ritgen; Claudia Pietschmann; Wolfram Klapper; Ioannis Anagnostopoulos; Ralf U Trappe Journal: Ann Hematol Date: 2021-05-11 Impact factor: 3.673
Authors: Cristina Valencia-Sanchez; Kristen K Steenerson; Katalin Kelemen; Robert Orenstein; Shimon Kusne; Marie F Grill Journal: J Neurovirol Date: 2019-01-03 Impact factor: 2.643